Literature DB >> 8363373

In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

J M Levin1, J A Nelson, J Segreti, B Harrison, C A Benson, F Strle.   

Abstract

The in vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents was investigated. The antimicrobial agents evaluated included ceftizoxime, FK037, cefotaxime, dirithromycin, clarithromycin and its metabolite 14-hydroxy-clarithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and ofloxacin. Isolates of B. burgdorferi tested included two reference strains (B31 and ATCC 53899), six isolates from the midwestern United States, and three from Europe. A broth macrodilution method was used to determine MICs and MBCs. B. burgdorferi was inhibited by < or = 0.5 micrograms of each of the agents except the quinolones per ml. The MBCs for 90% of strains tested of ceftizoxime, FK037, clarithromycin, 14-OH clarithromycin, and dirithromycin (< or = 1.0 microgram of each per ml) were superior to those of amoxicillin (2.0 micrograms/ml) and doxycycline (4.0 micrograms/ml). Further in vivo studies are warranted to determine whether these agents may be efficacious in the treatment of Lyme borreliosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363373      PMCID: PMC187991          DOI: 10.1128/AAC.37.7.1444

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

Review 2.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin.

Authors:  R C Johnson; C Kodner; M Russell; D Girard
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

Review 5.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  1989-08-31       Impact factor: 91.245

6.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  In vitro and in vivo susceptibility of Borrelia burgdorferi.

Authors:  V P Mursic; B Wilske; G Schierz; M Holmburger; E Süss
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

8.  Bird-feeding ticks transstadially transmit Borrelia burgdorferi that infect Syrian hamsters.

Authors:  J F Anderson; L A Magnarelli; K C Stafford
Journal:  J Wildl Dis       Date:  1990-01       Impact factor: 1.535

9.  In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.

Authors:  W A Agger; S M Callister; D A Jobe
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.

Authors:  S E Johnson; G C Klein; G P Schmid; J C Feeley
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  16 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.

Authors:  Kendal M Galbraith; Amanda C Ng; Betsy J Eggers; Craig R Kuchel; Christian H Eggers; D Scott Samuels
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.

Authors:  Martin Sicklinger; Ralf Wienecke; Uwe Neubert
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.

Authors:  R Murgia; F Marchetti; M Cinco
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry.

Authors:  Y F Liu; L C Lim; K Schell; S D Lovrich; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

6.  In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.

Authors:  R J Kazragis; L L Dever; J H Jorgensen; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.

Authors:  V Preac Mursic; W Marget; U Busch; D Pleterski Rigler; S Hagl
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 8.  Diagnosis, treatment, and prevention of Lyme disease in children.

Authors:  Stephen C Eppes
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 9.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

10.  In vitro activity of rokitamycin, a new macrolide, against Borrelia burgdorferi.

Authors:  M Cinco; D Padovan; G Stinco; G Trevisan
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.